{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T06:39:35Z","timestamp":1794724775272,"version":"4.9.1"},"reference-count":25,"publisher":"American Association for Cancer Research (AACR)","issue":"6","funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA 008748"],"award-info":[{"award-number":["P30 CA 008748"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA 240139"],"award-info":[{"award-number":["P30 CA 240139"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Genomic antigen loss is a recurring mechanism of resistance to chimeric antigen receptor T-cell (CAR-T) and T-cell engagers (TCE) in relapsed\/refractory multiple myeloma (RRMM). Yet, it remains unclear whether these events are acquired under treatment or merely selected from preexisting, undetectable clones. By leveraging chemotherapy mutational signatures as temporal barcodes within whole-genome sequencing data, we could time genomic antigen escape in 4 of 11 patients with RRMM. In all cases, the biallelic loss was driven by genomic events acquired after exposure to BCMA- and GPCR5D-targeted CAR-T\/TCE and not present at baseline. Longitudinal digital PCR analysis corroborated that resistance mutations were undetectable at therapy initiation but emerged preceding relapse. Among 752 newly diagnosed patients, only 2.7% and 9% had monoallelic inactivation of TNFRSF17 and GPCR5D, respectively, with no biallelic loss. Our findings suggest limited utility of mutational screening prior to CAR-T\/TCE while underscoring the importance of dynamic surveillance during therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Multiple myeloma has been demonstrated to recurrently develop resistance to T-cell redirection via genomic antigen escape. By leveraging chemotherapy mutational signatures, we demonstrate that somatic antigen-escape mechanisms are uniformly acquired following treatment initiation and not selected from among preexisting clones, emphasizing the importance of dynamic longitudinal surveillance for their emergence.<\/jats:p>\n                    <jats:p>See related commentary by Kauer et al., p. 532<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2643-3230.bcd-25-0005","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T19:56:06Z","timestamp":1757015766000},"page":"572-579","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Timing Genomic Antigen Loss in Multiple Myeloma Treated with T Cell\u2013Redirecting Immunotherapies"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-1852-3495","authenticated-orcid":false,"given":"Marios","family":"Papadimitriou","sequence":"first","affiliation":[{"name":"1Myeloma Division, University of Miami, Sylvester Comprehensive Cancer Center, Miami, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7688-6843","authenticated-orcid":false,"given":"Sungwoo","family":"Ahn","sequence":"additional","affiliation":[{"name":"2Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8638-9365","authenticated-orcid":false,"given":"Benjamin T.","family":"Diamond","sequence":"additional","affiliation":[{"name":"1Myeloma Division, University of Miami, Sylvester Comprehensive Cancer Center, Miami, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8353-0848","authenticated-orcid":false,"given":"Holly","family":"Lee","sequence":"additional","affiliation":[{"name":"2Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3135-8227","authenticated-orcid":false,"given":"John B.","family":"McIntyre","sequence":"additional","affiliation":[{"name":"3Cancer Translational Research Core, Arthur Child Cancer Centre, Calgary, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2286-0656","authenticated-orcid":false,"given":"Marietta","family":"Truger","sequence":"additional","affiliation":[{"name":"4MLL Munich Leukemia Laboratory, Munich, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3137-6847","authenticated-orcid":false,"given":"Michael A.","family":"Durante","sequence":"additional","affiliation":[{"name":"1Myeloma Division, University of Miami, Sylvester Comprehensive Cancer Center, Miami, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2746-0053","authenticated-orcid":false,"given":"Bachisio","family":"Ziccheddu","sequence":"additional","affiliation":[{"name":"1Myeloma Division, University of Miami, Sylvester Comprehensive Cancer Center, Miami, Florida."},{"name":"5Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1053-5454","authenticated-orcid":false,"given":"Katalin","family":"Osz","sequence":"additional","affiliation":[{"name":"3Cancer Translational Research Core, Arthur Child Cancer Centre, Calgary, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6485-4839","authenticated-orcid":false,"given":"Ola","family":"Landgren","sequence":"additional","affiliation":[{"name":"1Myeloma Division, University of Miami, Sylvester Comprehensive Cancer Center, Miami, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9536-9649","authenticated-orcid":false,"given":"Leo","family":"Rasche","sequence":"additional","affiliation":[{"name":"6Department of Internal Medicine, University Hospital of Wu\u0308rzburg, Wu\u0308rzburg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7353-7034","authenticated-orcid":false,"given":"Nizar J.","family":"Bahlis","sequence":"additional","affiliation":[{"name":"2Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2595-3647","authenticated-orcid":false,"given":"Paola","family":"Neri","sequence":"additional","affiliation":[{"name":"2Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5017-1620","authenticated-orcid":false,"given":"Francesco","family":"Maura","sequence":"additional","affiliation":[{"name":"1Myeloma Division, University of Miami, Sylvester Comprehensive Cancer Center, Miami, Florida."},{"name":"5Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2025,9,4]]},"reference":[{"key":"2025110303130815500_bib1","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"key":"2025110303130815500_bib2","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","article-title":"GPRC5D-Targeted CAR T cells for myeloma","volume":"387","author":"Mailankody","year":"2022","journal-title":"N Engl J Med"},{"key":"2025110303130815500_bib3","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma. Reply","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"key":"2025110303130815500_bib4","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"2025110303130815500_bib5","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"2025110303130815500_bib6","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(21)01338-6","article-title":"Teclistamab, a B-cell maturation antigen x CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study","volume":"398","author":"Usmani","year":"2021","journal-title":"Lancet"},{"key":"2025110303130815500_bib7","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41591-021-01245-5","article-title":"Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma","volume":"27","author":"Da Vi\u00e0","year":"2021","journal-title":"Nat Med"},{"key":"2025110303130815500_bib8","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","article-title":"Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma","volume":"29","author":"Lee","year":"2023","journal-title":"Nat Med"},{"key":"2025110303130815500_bib9","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/s41467-021-21177-5","article-title":"Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma","volume":"12","author":"Samur","year":"2021","journal-title":"Nat Commun"},{"key":"2025110303130815500_bib10","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1038\/s43018-023-00625-9","article-title":"Acquired resistance to a GPRC5D directed T-cell engager in multiple myeloma is mediated by genetic or epigenetic target inactivation","volume":"4","author":"Derrien","year":"2023","journal-title":"Nat Cancer"},{"key":"2025110303130815500_bib11","doi-asserted-by":"crossref","first-page":"6599","DOI":"10.1182\/bloodadvances.2023010025","article-title":"Monoallelic deletion of BCMA is a frequent feature in multiple myeloma","volume":"7","author":"Samur","year":"2023","journal-title":"Blood Adv"},{"key":"2025110303130815500_bib12","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41467-017-00296-y","article-title":"Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing","volume":"8","author":"Rasche","year":"2017","journal-title":"Nat Commun"},{"key":"2025110303130815500_bib13","doi-asserted-by":"crossref","first-page":"4517","DOI":"10.1038\/s41467-022-32145-y","article-title":"The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states","volume":"13","author":"Rasche","year":"2022","journal-title":"Nat Commun"},{"key":"2025110303130815500_bib14","doi-asserted-by":"crossref","first-page":"101145","DOI":"10.1016\/j.beha.2020.101145","article-title":"Reconstructing the evolutionary history of multiple myeloma","volume":"33","author":"Maura","year":"2020","journal-title":"Best Pract Res Clin Haematol"},{"key":"2025110303130815500_bib15","doi-asserted-by":"crossref","first-page":"e422","DOI":"10.1016\/S2352-3026(21)00130-7","article-title":"Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a singlearm, single-centre, phase 2 trial","volume":"8","author":"Diamond","year":"2021","journal-title":"Lancet Haematol"},{"key":"2025110303130815500_bib16","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1038\/s41467-020-17459-z","article-title":"Accelerated single cell seeding in relapsed multiple myeloma","volume":"11","author":"Landau","year":"2020","journal-title":"Nat Commun"},{"key":"2025110303130815500_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41375-021-01293-3","article-title":"The mutagenic impact of melphalan in multiple myeloma","volume":"35","author":"Maura","year":"2021","journal-title":"Leukemia"},{"key":"2025110303130815500_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-15740-9","article-title":"Timing the initiation of multiple myeloma","volume":"11","author":"Rustad","year":"2020","journal-title":"Nat Commun"},{"key":"2025110303130815500_bib19","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1038\/s41588-019-0525-5","article-title":"The mutational footprints of cancer therapies","volume":"51","author":"Pich","year":"2019","journal-title":"Nat Genet"},{"key":"2025110303130815500_bib20","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1200\/JCO.23.01277","article-title":"Genomic classification and individualized prognosis in multiple myeloma","volume":"42","author":"Maura","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025110303130815500_bib21","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1038\/s41591-022-01927-8","article-title":"Detection of early seeding of Richter transformation in chronic lymphocytic leukemia","volume":"28","author":"Nadeu","year":"2022","journal-title":"Nat Med"},{"key":"2025110303130815500_bib22","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1158\/2643-3230.BCD-20-0132","article-title":"Revealing the impact of structural variants in multiple myeloma","volume":"1","author":"Rustad","year":"2020","journal-title":"Blood Cancer Discov"},{"key":"2025110303130815500_bib23","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1056\/NEJMc2308544","article-title":"Genetic basis of relapse after GPRC5D-targeted CAR T cells","volume":"389","author":"Mi","year":"2023","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"2025110303130815500_bib24","doi-asserted-by":"crossref","first-page":"4688","DOI":"10.1182\/blood-2023-188080","article-title":"The impact of soluble BCMA and BCMA gain on anti-BCMA immunotherapies in multiple myeloma","volume":"142","author":"Lee","year":"2023","journal-title":"Blood"},{"key":"2025110303130815500_bib25","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1038\/s41467-025-56486-6","article-title":"Deciphering response dynamics and treatment resistance from circulating tumor DNA after CAR T-cells in multiple myeloma","volume":"16","author":"Hosoya","year":"2025","journal-title":"Nat Commun"}],"container-title":["Blood Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-25-0005\/3648347\/bcd-25-0005.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-25-0005\/3659344\/bcd-25-0005.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/6\/6\/572\/3663404\/bcd-25-0005.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/6\/6\/572\/3663404\/bcd-25-0005.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T08:13:19Z","timestamp":1762157599000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article\/6\/6\/572\/766817\/Timing-Genomic-Antigen-Loss-in-Multiple-Myeloma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,4]]},"references-count":25,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,9,4]]},"published-print":{"date-parts":[[2025,11,3]]}},"URL":"https:\/\/doi.org\/10.1158\/2643-3230.bcd-25-0005","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2643-3230.30516489","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.30516486","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2643-3230.c.8126001","asserted-by":"object"}]},"ISSN":["2643-3230","2643-3249"],"issn-type":[{"value":"2643-3230","type":"print"},{"value":"2643-3249","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,4]]}}}